Waterfront has advised male fertility company ExSeed Health on a £2.5M / $3.4M seed extension round, led by Ascension and with participation from Trifork, Hambro Perks, and R42 Group. The investment will drive further European expansion and is a step forward in ExSeed’s mission to tackle rising male infertility.

The investment comes after ExSeed continued making big strides in the fertility space, with a 4X growth on the previous year and over 15,000 tests conducted through the businesses app.

The Waterfront team advising on the deal was led by partner Matt Cunningham who was supported by associate Charlotte Lang.

ExSeed’s co-founder and CEO Morten G. Ulsted said; We have worked with Waterfront for several years on a wide range of matters and we value the team’s expertise. The team have taken the time to listen and learn about our business and have skilfully navigated us through our latest investment round. We look forward to working with the Waterfront team again in the future.”